

Amendments to the Specification:

Please amend the Specification as follows:

On page 3, line 28, before the paragraph starting "Description of the Invention" on page 4, please add the following heading and paragraphs:

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Pre-saturation of $\text{Al}(\text{OH})_3$ with PLG (106 residues).

Figure 2: Competition between PRP-T and PLG (85 residues).

Figure 3: Evaluation of the Hib-PLG formulations in the rabbit model.

Figure 4: Evaluation of immunogenicity and impact of PLG on new PLG Hib formulations administered with Infanrix penta in the infant rat model.

Figure 5: Schematic representation of adsorption and flocculation.

Figure 6: Scheme of clinical trial.

Figure 7: Optical microscope picture of Infanrix-peNTa (DTPaHepBIPV).

Figure 8: Optical microscope picture of sample flocculating when $5\mu\text{g}$ saccharide of PRP-TT is added to the sample.

Figure 9: Optical microscope picture showing no flocculation in the presence of $200\ \mu\text{M}$ PLG Mw 2,200 (Sigma).

Figure 10: Optical microscope picture showing no observable flocculations in DTPw controls.

Figure 11: Optical microscope picture showing observable flocculations in DTPw samples with reconstituted MenACHib-TT.

Figure 12: Optical microscope picture showing that DTPwHepB/MenACHib with 250 μ M PLG exhibits reduced flocculation.